title: Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction.
abstract: Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor. Maximal safe surgical resection followed by adjuvant partial brain radiation with concurrent and adjuvant temozolomide (TMZ) (oral alkylating agent) is the standard of care. Five years survival in TMZ treated patient reaches 9.8%. We aimed to summarize the changes in the management of GBM beyond conventional temozolomide based adjuvant treatment. We searched the PUBMED with the following key words: Glioblastoma, phase III trial, Phase II trial, adjuvant treatment in GBM. Clinical research has found a wide range of molecular aberrations in GBM and attempts are being made to further improve survival with the addition of different classes of drugs. Angiogenesis inhibitors, oncolytic vaccines, dose dense TMZ, and anti-epidermal growth factor receptor monoclonal antibody in phase III trials have failed to improve survival. Recent studies have also shown that the management strategies might be different and needs to be customized as per the age of patients such as pediatric and elderly patients. In addition, treatments should be personalized depending on the molecular aberrations. We reviewed all published phase III trials for newly diagnosed GBM as well as also looked into possible future directions in this review. Limited progress has happed beyond conventional TMZ in the adjuvant treatment of GBM. Newer insights are emerging about treatment intensification and introduction of newer molecular targeted drugs with more information about molecular aberrations.
authors.affiliation: Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Supriya
authors.initials: S
authors.lastname: Mallick
authors.affiliation: Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Ajeet Kumar
authors.initials: AK
authors.lastname: Gandhi
authors.affiliation: Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India; National Cancer Institute, (2nd Campus) All India Institute of Medical Sciences, Jhajjar, Haryana, India.
authors.forename: Goura Kishor
authors.initials: GK
authors.lastname: Rath
keywords: Bevacizumab; glioblastoma; hypofractionated radiotherapy; temozolomide; vaccine
references.citation: Cancer Cell. 2010 Jan 19;17(1):98-110
references.pmid: 20129251
references.citation: Neoplasia. 2010 Sep;12(9):675-84
references.pmid: 20824044
references.citation: J Clin Oncol. 2015 Jul 10;33(20):2296-302
references.pmid: 26014296
references.citation: Hum Gene Ther. 1998 Aug 10;9(12):1769-74
references.pmid: 9721087
references.citation: Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1206-11
references.pmid: 23182702
references.citation: Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):793-800
references.pmid: 24495592
references.citation: Clin Adv Hematol Oncol. 2012 Apr;10(4):240-6
references.pmid: 22706484
references.citation: Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):390-7
references.pmid: 20097489
references.citation: J Neurooncol. 2015 Feb;121(3):489-97
references.pmid: 25479829
references.citation: J Neurooncol. 2012 Aug;109(1):195-203
references.pmid: 22555992
references.citation: Clin Cancer Res. 2014 Oct 1;20(19):5023-31
references.pmid: 25107913
references.citation: Lancet Oncol. 2013 Aug;14(9):823-33
references.pmid: 23850491
references.citation: Childs Nerv Syst. 2010 Nov;26(11):1613-8
references.pmid: 20585787
references.citation: Lancet Oncol. 2012 Sep;13(9):916-26
references.pmid: 22877848
references.citation: Radiother Oncol. 2010 Dec;97(3):377-81
references.pmid: 20855119
references.citation: Int J Cancer. 2015 Nov 15;137(10):2343-53
references.pmid: 25994230
references.citation: J Neurooncol. 2013 Jan;111(1):33-9
references.pmid: 23086432
references.citation: J Clin Oncol. 2015 Jul 1;33(19):2166-75
references.pmid: 26014298
references.citation: Neuro Oncol. 2011 Dec;13(12):1331-8
references.pmid: 21896554
references.citation: Curr Opin Investig Drugs. 2003 Jun;4(6):741-5
references.pmid: 12901235
references.citation: Indian J Med Paediatr Oncol. 2015 Apr-Jun;36(2):99-104
references.pmid: 26157286
references.citation: Eur J Cancer. 2012 Sep;48(14):2192-202
references.pmid: 22608262
references.citation: Neuro Oncol. 2014 Dec;16(12):1607-17
references.pmid: 24997139
references.citation: Lancet Oncol. 2009 May;10(5):459-66
references.pmid: 19269895
references.citation: J Clin Oncol. 2015 Sep 1;33(25):2735-44
references.pmid: 26124478
references.citation: J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
references.pmid: 11895036
references.citation: Lancet Oncol. 2012 Jul;13(7):707-15
references.pmid: 22578793
references.citation: J Neurooncol. 2013 Aug;114(1):111-6
references.pmid: 23729276
references.citation: Neuro Oncol. 2013 Oct;15(10):1405-12
references.pmid: 23911595
references.citation: Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):473-8
references.pmid: 18554821
references.citation: N Engl J Med. 2014 Feb 20;370(8):699-708
references.pmid: 24552317
references.citation: Eur J Cancer. 2015 Mar;51(4):522-532
references.pmid: 25616647
references.citation: J Neurooncol. 2011 Jul;103(3):595-602
references.pmid: 21052775
references.citation: Eur J Cancer. 2013 Jun;49(9):2161-9
references.pmid: 23566417
references.citation: Neurooncol Pract. 2016 Mar;3(1):39-47
references.pmid: 31579520
references.citation: Nat Rev Neurosci. 2007 Aug;8(8):610-22
references.pmid: 17643088
references.citation: Semin Oncol. 2014 Oct;41 Suppl 6:S25-34
references.pmid: 25213871
references.citation: Am J Surg Pathol. 1998 Jul;22(7):816-26
references.pmid: 9669344
references.citation: Cancer Res. 2009 Jul 15;69(14):5851-9
references.pmid: 19584289
references.citation: Lancet Oncol. 2014 Sep;15(10):1100-8
references.pmid: 25163906
references.citation: Cancer Chemother Pharmacol. 2013 Feb;71(2):511-21
references.pmid: 23228988
references.citation: J Clin Oncol. 2013 Nov 10;31(32):4085-91
references.pmid: 24101040
references.citation: N Engl J Med. 2012 Feb 9;366(6):520-9
references.pmid: 22149876
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4189-99
references.pmid: 18757334
references.citation: J Cancer Res Ther. 2013 Jul-Sep;9(3):381-6
references.pmid: 24125970
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: N Engl J Med. 2014 Feb 20;370(8):709-22
references.pmid: 24552318